Senior Solution Architect

Roivant Sciences (NASDAQ:ROIV) insider Mayukh Sukhatme sells 243,177 shares. August 18, 2026 Key points. * Roivant Sciences insider Mayukh Sukhatme sold 243,177 shares at an average price of $36.23, generating approximately $8.81 million. He retained 18.63 million shares after the transaction and also reported two additional sales totaling about $15.35 million. * ROIV shares rose 3.1% to $37.37, near the company's 12-month high of $37.46. Roivant reported a quarterly loss of $0.26 per share, better than analysts' expected $0.30 loss, but revenue of $1.44 million fell short of the $2.06 million consensus estimate. * Analyst sentiment remains broadly positive, with a "Moderate Buy" consensus and an average price target of $35.14, while institutional investors own 64.76% of the company. * Five stocks we like better than Roivant Sciences. Roivant Sciences Ltd. (NASDAQ:ROIV - Get Free Report) insider Mayukh Sukhatme sold 243,177 shares of the business's stock in a transaction dated Friday, August 14th. The stock was sold at an average price of $36.23, for a total value of $8,810,302.71. Following the transaction, the insider owned 18,630,739 shares of the company's stock, valued at approximately $674,991,673.97. The trade was a 1.29% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Mayukh Sukhatme also recently made the following trade(s): * On Monday, August 17th, Mayukh Sukhatme sold 284,707 shares of Roivant Sciences stock. The shares were sold at an average price of $36.25, for a total value of $10,320,628.75. * On Tuesday, August 18th, Mayukh Sukhatme sold 136,942 shares of Roivant Sciences stock. The shares were sold at an average price of $36.73, for a total value of $5,029,879.66. Roivant Sciences trading up 3.1%. Shares of NASDAQ ROIV traded up $1.13 during midday trading on Tuesday, hitting $37.37. 6,409,504 shares of the company's stock were exchanged, compared to its average volume of 5,396,372. Roivant Sciences Ltd. has a 12-month low of $11.54 and a 12-month high of $37.46. The company has a market cap of $26.99 billion, a price-to-earnings ratio of -70.51 and a beta of 1.12. The business's fifty day moving average price is $34.16 and its two-hundred day moving average price is $30.17. Roivant Sciences (NASDAQ:ROIV - Get Free Report) last announced its earnings results on Friday, August 7th. The company reported ($0.26) earnings per share for the quarter, beating analysts' consensus estimates of ($0.30) by $0.04. Roivant Sciences had a negative net margin of 3,534.96% and a negative return on equity of 22.94%. The business had revenue of $1.44 million for the quarter, compared to the consensus estimate of $2.06 million. Equities analysts expect that Roivant Sciences Ltd. will post -1.83 earnings per share for the current fiscal year. Analyst ratings changes. ROIV has been the subject of a number of analyst reports. Bank of America reissued a "neutral" rating on shares of Roivant Sciences in a research note on Friday, July 31st. Piper Sandler reaffirmed an "overweight" rating on shares of Roivant Sciences in a research note on Thursday, May 21st. Leerink Partners set a $42.00 price target on shares of Roivant Sciences in a report on Thursday, May 21st. Sanford C. Bernstein raised shares of Roivant Sciences to a "strong-buy" rating in a research report on Wednesday, July 29th. Finally, Citigroup raised their price target on shares of Roivant Sciences from $42.00 to $46.00 and gave the stock a "buy" rating in a report on Monday, August 10th. One investment analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus target price of $35.14. Institutional inflows and outflows. A number of hedge funds and other institutional investors have recently bought and sold shares of ROIV. SBI Securities Co. Ltd. grew its position in shares of Roivant Sciences by 1,740.3% in the 4th quarter. SBI Securities Co. Ltd. now owns 1,233 shares of the company's stock worth $27,000 after buying an additional 1,166 shares during the last quarter. Allworth Financial LP lifted its holdings in Roivant Sciences by 48.1% in the third quarter. Allworth Financial LP now owns 1,795 shares of the company's stock worth $27,000 after buying an additional 583 shares during the period. Kestra Advisory Services LLC bought a new position in shares of Roivant Sciences in the 4th quarter worth about $47,000. Parallel Advisors LLC boosted its stake in Roivant Sciences by 33.7% in the 1st quarter. Parallel Advisors LLC now owns 2,065 shares of the company's stock worth $57,000 after purchasing an additional 520 shares in the last quarter. Finally, CIBC Private Wealth Group LLC raised its position in Roivant Sciences by 7,614.3% in the 4th quarter. CIBC Private Wealth Group LLC now owns 2,700 shares of the company's stock worth $59,000 after buying an additional 2,665 shares during the last quarter. Institutional investors own 64.76% of the company's stock. Roivant Sciences company profile. Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as "Vants." Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines. The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women's health. This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected]. Continue following MarketBeat Before you consider Roivant Sciences, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Roivant Sciences wasn't on the list. While Roivant Sciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

Roivant Sciences Q1 earnings call highlights. August 7, 2026 Key points. * Roivant expects a busy second half of 2026, highlighted by a potential FDA approval and launch of brepocitinib for dermatomyositis by the end of September, plus clinical readouts in noninfectious uveitis, PH-ILD and cutaneous lupus. * Brepocitinib development is expanding, with Phase III trials underway in cutaneous sarcoidosis and lichen planopilaris. Roivant also plans further updates on Immunovant's IMVT-1402 programs in rheumatoid arthritis and Graves' disease. * Roivant reported nearly $4 billion in cash before receiving about $772 million from its Moderna settlement, repurchased roughly $200 million of stock during the quarter and said it will continue buybacks while funding its pipeline. * MarketBeat previews top five stocks to own in September. Roivant Sciences NASDAQ: ROIV said it expects a busy second half of 2026, with a potential launch of brepocitinib in dermatomyositis, several clinical readouts and additional regulatory discussions across its pipeline. Chief Executive Officer Matt Gline characterized the quarter as relatively quiet but said the company has advanced several priorities outlined at its investor day. Those include the anticipated brepocitinib launch, development work at Immunovant, progress in litigation-related matters and continued capital returns. "The next 6-12 months are in many ways busier than the prior 6-12 months for us," Gline said on the company's first-quarter earnings call. Brepocitinib launch and pipeline progress. Roivant said brepocitinib, which is under priority FDA review for dermatomyositis, is expected to launch by the end of September if it receives approval. Gline said the commercial and patient-support teams at Priovant have been built, trained and are ready for a potential launch. Management reiterated that it intends to pursue a "slow and steady" launch rather than focus on near-term sales metrics. Gline said the company is seeking to establish access, patient-support, institutional and physician-engagement infrastructure that can support brepocitinib across multiple potential indications beyond dermatomyositis. Gline said physicians and patients have expressed enthusiasm for new treatment options in dermatomyositis, a condition in which patients often use multiple therapies and remain dissatisfied with available treatments. He also said Roivant expects brepocitinib's label to include the boxed warnings associated with other JAK inhibitors, but management believes physicians will weigh those considerations against the severity of dermatomyositis and risks associated with treatments such as high-dose steroids and immunosuppressants. The company also began enrolling patients in a Phase III trial of brepocitinib for cutaneous sarcoidosis. The 140-patient study will compare 45 milligrams of brepocitinib with placebo over 16 weeks and uses a primary endpoint of at least a 50% response on the Cutaneous Sarcoidosis Activity and Morphology Instrument, or CSAMI. Participants will undergo a mandatory steroid taper from week two through week eight. Roivant expects top-line data from that study in 2028. Gline said the company estimates there are approximately 40,000 U.S. patients with cutaneous sarcoidosis and pointed to potential overlap with ocular and pulmonary manifestations of sarcoidosis. Roivant also said its registrational study of brepocitinib in lichen planopilaris is enrolling "extremely well," according to Gline. The company added lichen planopilaris as a fourth brepocitinib indication earlier this year. Second-Half readouts. Roivant expects several important data events during the second half of 2026. These include top-line data from a Phase III study of brepocitinib in noninfectious uveitis, which Gline said could represent an opportunity comparable in size to dermatomyositis. The company also expects top-line data from the Phase II FOCUS study of mosliciguat in pulmonary hypertension associated with interstitial lung disease, or PH-ILD. Management said it is looking for a clear signal in pulmonary vascular resistance, or PVR, while noting that the trial is not powered to provide a definitive assessment of six-minute walk distance. Gline said Roivant believes inhaled vasodilation could benefit PH-ILD patients, though the Phase II study is intended to assess whether results seen in pulmonary arterial hypertension translate to the PH-ILD population. He said the company designed the study with limits on emphysema to support broad enrollment while seeking to maximize the therapy's potential benefit. For mosliciguat, Roivant said monotherapy data will be released before data from an open-label combination study, which began later and remains in enrollment. Management said the combination trial is intended to add safety experience and provide information that may help inform Phase III trial design. Roivant also expects a proof-of-concept readout in cutaneous lupus erythematosus, or CLE, during the second half. The first disclosure will include 12-week data comparing a 600-milligram dose with placebo. Gline described the trial as a small fact-finding study intended to help the company assess treatment benefit and determine whether to advance the program. Immunovant programs and litigation. Roivant plans to provide a fuller update later this year on Immunovant's IMVT-1402 program in difficult-to-treat rheumatoid arthritis. That update could include results from the randomized-withdrawal portion of the study, feedback from an anticipated FDA discussion and potential next steps for registrational development. The company is also advancing IMVT-1402 in Graves' disease. Gline said Roivant views the condition as a market with substantial unmet need, rather than one defined primarily by competition among emerging mechanisms. He said the company expects to be the first to bring an advanced therapy to the market if its program succeeds. Separately, Roivant received the initial payment from its settlement with Moderna. Gline said the $950 million payment included approximately $770 million for Genevant and the remainder for Arbutus. He said litigation under Section 1498 remains under review at the Federal Circuit and could result in an additional $1.3 billion with a favorable outcome. Roivant also filed international lawsuits against Pfizer and BioNTech, including actions in Canada and the Unified Patent Court, during July. Financial position and capital returns. Roivant reported approximately $200 million in research-and-development expense for the quarter. Non-GAAP adjusted general and administrative expense was just under $100 million, while GAAP general and administrative expense was $166 million. The company reported cash of just under $4 billion before receipt of approximately $772 million associated with the Moderna settlement payment. Roivant repurchased about $200 million of stock during the quarter, with additional repurchases in March, after accelerating its buyback activity following the Moderna settlement announcement. Gline said the company will continue repurchasing shares under its existing authorizations while preparing for a catalyst-rich period that could include multiple clinical readouts, regulatory filings and commercial launches through the end of 2028. About Roivant Sciences (NASDAQ:ROIV). Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as "Vants." Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines. The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women's health. This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected]. Continue following MarketBeat Before you consider Roivant Sciences, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Roivant Sciences wasn't on the list. While Roivant Sciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys. Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming to the United States, and there are four ways that investors can gain exposure to this new robotics revolution. Plus, learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.